BioWorld Asia

Oct. 1, 2008

Nitec Pharma Gets $22M to Fund Lodotra Launch

With a first European approval for its rheumatoid arthritis drug Lodotra imminent, Nitec Pharma AG raised CHF24 million (US$22 million) in a private equity round led by Munich, Germany-based TVM Capital. (BioWorld International) Read More

Telormedix Gets $19M in Series A Round

Elucidation of Cancer Growth Yields Potential Drug Targets

Nextech Closes Oncology Fund with $65M in Hand

Phynova Focusing on China, Pipeline and Conserving Cash

Genetically Modified Cotton is Good Neighbor to Other Crops

NicOx Signs Naproxcinod Agreement with Capsugel

ExonHit Therapeutics to Provide Genomic Services to French CRO

FDA Investigating Deaths in Ortho's German Stroke Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...